现代医药卫生2025，Vol.41Issue(9)：2029-2033,5.DOI:10.3969/j.issn.1009-5519.2025.09.003
Ahlqvist分型驱动2型糖尿病精准诊疗:跨种族验证、并发症风险分层与临床转化
Ahlqvist classification enhances the precision of diagnosis and treatment in type 2 diabetes:cross-ethnic validation,risk stratification for complications,and clinical applicability
摘要
Abstract
The traditional classification of diabetes is inadequate for meeting the demands of precision medicine of type 2 diabetes mellitus(T2DM).The Ahlqvist classification,which is based on pathophysiologi-cal characteristics and integrates clinical variables with machine learning techniques,categorizes T2DM into five distinct subtypes,that is,severe autoimmune diabetes,severe insulin deficiency(SIDD),severe insulin re-sistance(SIRD),mild obesity-related(MOD),and mild age-related(MARD)have been verified across races(covering more than 20 000 patients worldwide).The core of this classification driving precision diagnosis and treatment lies in subtype-specific complication risk stratification[risk of nephropathy in SIRD(hazard ratio=2.40),risk of stroke in MOD(odds ratio=1.07)],optimization of individualized treatment strategies(met-formin,thiazolidinedione drugs combined with sodium-glucose cotransporter 2 inhibitors were preferred for SIRD),and screening differentiation[MOD strengthens stroke monitoring,severe insulin deficiency/SIRD in-tervention lifestyle risks(such as a smoking rate greater than 50%),etc.The TANABE team in Japan had constructed a practical model without HOMA2(with an accuracy rate of 82.9%),breaking through the appli-cation barriers in resource-scarce areas;however,dynamic subtype conversion and insufficient integration of non-metabolic factors remain challenges.Ahlqvist parting for T2DM high-risk population stratification,targe-ted prevention,individualized treatment provides evidence-based framework,promoted to the transformation of precision and diabetes management.关键词
2型糖尿病/Ahlqvist分型/精准诊疗/跨种族验证/并发症风险分层/临床转化/综述Key words
Type 2 diabetes/Ahlqvist classification/Precision of diagnosis and treatment/Inter-racial validation/Complications risk stratification/Clinical transformation/Review分类
医药卫生引用本文复制引用
石凌峰,胡炯宇,唐梦佳,杨文静,张喻平..Ahlqvist分型驱动2型糖尿病精准诊疗:跨种族验证、并发症风险分层与临床转化[J].现代医药卫生,2025,41(9):2029-2033,5.基金项目
国家自然科学基金项目(82300992). （82300992）
